NEW YORK, March 7 – Sequenom has sold a MassArray system to genetic testing giant Quest Diagnostics, Sequenom said Wednesday.
Quest will use the MassArray system to identify disease-associated genetic variations and to determine susceptibility to hereditary conditions. The system has been installed at Nichols Institute, Quest's center for research and development, the companies said.
"As the acknowledged leader in genetic testing, Quest's decision to purchase the MassArray system is a significant testament to the quality and performance of our products," said Sequenom CEO Toni Schuh in a statement. “Improved gene-based diagnostics is perhaps the most immediate benefit of the human genome sequencing effort and no tool can ensure more accurate results than our MassArray system.”
The parties did not disclose how much Quest paid for the MassArray system. Previously, Sequenom has said the MassArray costs between $400,000 and $1.1 million depending on the consumables .
In 2000, Sequenom placed 22 MassArray systems in seven different countries. Sequenom’s private sector MassArray customers include Hitachi, Gemini Genomics, Invitrogen, Ag Research Limited of New Zealand, Genaissance Pharmaceuticals, Integrated DNA technologies, American Home Products, and Metabion GmbH.
Sequenom's public sector customers include the Whitehead Institute/MIT Center for Genome Research , the National Human Genome Research Institute, the Sanger Center, and Germany’s National Research Center for Environment and Health.